BCL2 and leukemia: In this work, we show that inhibiting MIF induces the death of leukemia cell lines and primary blasts and reprograms M2-like MΦ orientation when combined with GM-CSF, leading to blast cell death and reversal of resistance to therapies targeting FLT3-ITD or BCL-2 in vitro.